Clinical management of plasma cell leukaemia

Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer

Biomarkers of pembrolizumab response in head and neck cancer

Safety indications in mouse models treated with full doses of MEK inhibitors and SHP099

Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL

Front-line therapy of DIPG using IDO inhibitor with radiation and chemotherapy

Impact of microbiome on head and neck cancers

First-in-human trial results of RET targeted BLU-667

Treating RET alterations with novel therapy BLU-667

AKT inhibitors in research and application

Effects of dasatinib on xenograft lung tumour models with YES1 overexpression

Novel gene biomarkers in multiple cancers derived from non-malignant breast phenotypes